【基石药业-B(02616.HK)公布Nofazinlimab治疗肝细胞癌的国际多中心 III期研究的最新进展】智通财经

智通财经

07-04

【基石药业-B(02616.HK)公布Nofazinlimab治疗肝细胞癌的国际多中心 III期研究的最新进展】智通财经APP讯，基石药业-B(02616.HK)公布有关CS1003-305研究的最新进展，CS1003-305研究是一项国际多中心、双盲、随机对照的III期注册研究，在全球范围内设有74家研究中心，旨在评估PD-1单抗nofazinlimab(CS1003)联合仑伐替尼对比安慰剂联合仑伐替尼一线治疗不可切除或转移性肝细胞癌(HCC)患者的有效性和安全性。该研究的主要终点为总生存期(OS)。关键次要终点包括盲态独立中心审阅(BICR)评估的无进展生存期(PFS)和客观缓解率(ORR)。

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2548394331"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2548394331\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2548394331?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-07-04 22:34","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2548394331","market":"hk","top_or_hot":-1,"title":"【基石药业-B(02616.HK)公布Nofazinlimab治疗肝细胞癌的国际多中心 III期研究的最新进展】智通财经","media":"智通财经","content":"<html><body><div>\n<div>\n<b>【基石药业-B(02616.HK)公布Nofazinlimab治疗肝细胞癌的国际多中心 III期研究的最新进展】</b>智通财经APP讯，基石药业-B(02616.HK)公布有关CS1003-305研究的最新进展，CS1003-305研究是一项国际多中心、双盲、随机对照的III期注册研究，在全球范围内设有74家研究中心，旨在评估PD-1单抗nofazinlimab(CS1003)联合仑伐替尼对比安慰剂联合仑伐替尼一线治疗不可切除或转移性肝细胞癌(HCC)患者的有效性和安全性。该研究的主要终点为总生存期(OS)。关键次要终点包括盲态独立中心审阅(BICR)评估的无进展生存期(PFS)和客观缓解率(ORR)。                </div>\n</div></body></html>","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【基石药业-B(02616.HK)公布Nofazinlimab治疗肝细胞癌的国际多中心 III期研究的最新进展】智通财经</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【基石药业-B(02616.HK)公布Nofazinlimab治疗肝细胞癌的国际多中心 III期研究的最新进展】智通财经\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-04 22:34 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.zhitongcaijing.com/immediately.html?type=ganggu><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【基石药业-B(02616.HK)公布Nofazinlimab治疗肝细胞癌的国际多中心 III期研究的最新进展】智通财经APP讯，基石药业-B(02616.HK)公布有关CS1003-305研究的最新进展，CS1003-305研究是一项国际多中心、双盲、随机对照的III期注册研究，在全球范围内设有74家研究中心，旨在评估PD-1单抗nofazinlimab(CS1003)联合仑伐替尼对比安慰剂联合...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=ganggu\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ORR","symbol_name":"Militia Long/Short Equity ETF","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","article_id":"2548394331","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2548394331","pubTimestamp":1751639654,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【基石药业-B(02616.HK)公布Nofazinlimab治疗肝细胞癌的国际多中心 III期研究的最新进展】智通财经APP讯，基石药业-B(02616.HK)公布有关CS1003-305研究的最新","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"ORR":"Militia Long/Short Equity ETF","BK1574":"生物医药B类股","BK7095":"多种金属与采矿","ORR.AU":"ORECORP LTD","OS":"Onestream Inc","III":"信息服务","BK4006":"钢铁","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","02616":"基石药业-B","BK4134":"信息科技咨询与其它服务","PFS":"Provident Financial Services Inc","BK4211":"区域性银行","PD":"PagerDuty, Inc.","HCC":"Warrior Met Coal LLC","BK1161":"生物科技","BK4097":"系统软件","BK4023":"应用软件","BK4195":"互助储蓄与抵押信贷金融服务","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC"},"translate_title":"[CStone Pharmaceuticals-B (02616. HK) announces the latest progress of the international multi-center phase III study of Nofazinlimab in the treatment of hepatocellular carcinoma] Zhitong Finance","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFS":1,"PD":1,"OS":1,"ORR.AU":1,"ORR":1,"III":1,"02616":1,"HCC":1},"content_text":"【基石药业-B(02616.HK)公布Nofazinlimab治疗肝细胞癌的国际多中心 III期研究的最新进展】智通财经APP讯，基石药业-B(02616.HK)公布有关CS1003-305研究的最新进展，CS1003-305研究是一项国际多中心、双盲、随机对照的III期注册研究，在全球范围内设有74家研究中心，旨在评估PD-1单抗nofazinlimab(CS1003)联合仑伐替尼对比安慰剂联合仑伐替尼一线治疗不可切除或转移性肝细胞癌(HCC)患者的有效性和安全性。该研究的主要终点为总生存期(OS)。关键次要终点包括盲态独立中心审阅(BICR)评估的无进展生存期(PFS)和客观缓解率(ORR)。","kind":"live","is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}